Evaluation of a transgenic mouse model for anti-human CEA radioimmunotherapeutics

Journal of Nuclear Medicine

Volumn 43, Issue 10, 2002, Pages 1368-1376

  Wilkinson, Robert W ^a   Ross, Elizabeth L ^a   Ellison, David ^a   Zimmermann, Wolfgang ^a   Snary, David ^a   Mather, Stephen J ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Carcinoembryonic antigen; Radio labeled antibody; Transgenic mice

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IODINE 125; MONOCLONAL ANTIBODY PR1; MONOCLONAL ANTIBODY PR1A3; N SUCCIMIDYL 3 (4 HYDROXY 3 IODOPHENYL)PROPIONATE I 125; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; CANCER TRANSPLANTATION; CELL TYPE; CONTROLLED STUDY; EVALUATION; GASTROINTESTINAL TRACT; GENE SEQUENCE; MOUSE; MOUSE STRAIN; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RADIOIMMUNOTHERAPY; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; GASTROINTESTINAL NEOPLASMS; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

EID: 0036789345     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Boon T, Old LJ. Tumor antigens. Curr Opin Immunol. 1997;9:681-683.
2. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9:67-81.
3. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal. 1991;5:344-366.
4. Landis SH, Murray T, Bolden S. Wingo PA. Cancer statistics. 1999. CA Cancer J Clin. 1999;49:8-31.
5. Shiverly JE. Beatty JD. CEA-related antigens: molecular biology and clinical significance. CRC Crit Rev Oncol Haematol. 1985;2:355-399.
6. Carriquiry LA, Pineyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer? Dis Colon Rectum. 1999;42:921-929.
7. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. J Clin Oncol. 1996;14:1383-1400.
8. Stein R, Juweid M, Mattes MJ, Goldenberg DM. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 133-I and 90-Y labeled Mabs. Cancer Biother Radiopharm. 1999;14:37-47.
9. Hand PH, Robbins PF, Salgaller ML, Poole DJ, Schlom J. Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies. Cancer Inmunol Immunother. 1993;36:65-75.
10. Hogan B, Beddington R, Constantini F. Lacy E. Manipulating the Mouse Embryo: A Laboratory Manual. New York, NY: Cold Spring Harbor Press; 1994.
11. Eades-Perner E-P, van der Putten H, Hirth A, et al. Mice transgenic for human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res. 1994;54:4169-4176
12. Peat N, Gendler SJ, Lalani EN, Duhig T, Taylor-Papadimitriou J. Tissue specific expression of a human polymorphic epithelial mucin (MUC 1) in transgenic mice. Cancer Res. 1992;52:1954-1960.
13. Wilkinson RW, Ross E, Lee-MacAry AE, et al. A transgenic mouse model for tumor immunotherapy: induction of an anti-idiotype response to human MUC1. Br J Cancer. 2000;83:1202-1208.
14. Acres B, Apostolopoulos V, Balloul J-M, et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother. 2000;48:588-594.
15. Goldenberg DM. Carcinoembryonic antigen as a target cancer antigen for radio-labeled antibodies: prospects for cancer imaging and therapy. Tumor Biol. 1995;16:62-73.
16. Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res. 1998;58:1469-1477.
17. Richman PI, Bodmer WF. Monoclonal antibodies to human colorectal epithelium: markers for differentiation and tumor characterization. Int J Cancer. 1987;39:317-328.
18. Stewart LMD, Young S, Watson G, et al. Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen. Cancer Immunol Immunother. 1999;47:299-306.
19. Thompson JA, Eades-Perner A-M, Ditter M, Muller WJ, Zimmermann W. Expression of transgenic carcinoembryonic antigen (CEA) in tumor-prone mice: an animal model for CEA-directed tumor immunotherapy. Int J Cancer. 1997;72:197-202.
20. Burchell J, Gendler SJ. Taylor-Papadimitriou J, et al. Development and characteristics of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987;47:5476-5482.
21. Sheahan K, O'Brien MJ, Burke B, Dervan PA, O'Keane JC. Gottlieb LS. Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies. Am J Clin Pathol. 1990;94:157-164.
22. Stalteri MA, Mather SJ, Technetium-99m labelling of anti-tumor antibody PR1A3 by by photoactivation. Eur J Nucl Med. 1996;23:178-187.
23. Brown BA, Comeau RD, Jones PL, et al. Pharmacokinetics of the monoclonal antibody B72.3 and its fragments labeled with either 1-125 or In-111. Cancer Res. 1987;47:1149-1154.
24. Granowska M, Britton KE, Mather SJ, et al. Radioimmunoscintigraphy with technetium-99m labelled monoclonal antibody, IA3, in colorectal cancer. Eur J Nucl Med. 1993;20:690-697.
25. Durbin H, Young S, Stewart LM, et al. An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PRIA3, Proc Natl Acad Sci USA. 1994;91:4313-4317.
26. Szalai G, Williams LE, Primus FJ. Tumor targeting with radiolabeled antibodies in a human carcinoembryonic antigen transgenic mouse model. Int J Cancer. 2000;85:751-756.
27. Moser AR. Pilot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in mouse. Science. 1990;247:322-324.
28. Mukherjee P, Ginardi AR, Madsen CS, et al. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred. J Immunol. 2000;165:3451-3460.